An overview of alternative splicing defects implicated in myotonic dystrophy type I A López-Martínez, P Soblechero-Martín, L de-la-Puente-Ovejero, ... Genes 11 (9), 1109, 2020 | 56 | 2020 |
Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies P Soblechero‐Martín, A López‐Martínez, L de la Puente‐Ovejero, ... Neuropathology and Applied Neurobiology 47 (6), 711-723, 2021 | 13 | 2021 |
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening P Soblechero-Martin, E Albiasu-Arteta, A Anton-Martinez, ... Scientific Reports, 18188, 2021 | 7 | 2021 |
Evaluation of exon skipping and dystrophin restoration in in vitro models of duchenne muscular dystrophy A López-Martínez, P Soblechero-Martín, V Arechavala-Gomeza Antisense RNA Design, Delivery, and Analysis, 217-233, 2022 | 3 | 2022 |
VP. 88 Characterisation of cell culture models of myotonic dystrophy type I by In-Cell Western technology and digital droplet PCR A López-Martínez, P Soblechero-Martín, C Catalli, A Jauregui-Barrutia, ... Neuromuscular Disorders 32, S132-S133, 2022 | | 2022 |
Optimisation of a Cell-Based Strategy for Rapid Evaluation of Compounds in Myotonic Dystrophy Type I A López-Martínez, P Soblechero-Martín, C Catalli, A Jauregi-Barrutia, ... 17th International Congress on Neuromuscular Diseases 9 (s1), S139, 2022 | | 2022 |
Búsqueda de compuestos moduladores de STAU1 mediante herramientas computacionales para su aplicación en la distrofia miotónica tipo I A López Martínez Universitat Oberta de Catalunya (UOC), 2022 | | 2022 |
DMD-BIOMARKERS: EP. 161 A novel cell-based screening assay for the identification of utrophin-upregulating compounds P Soblechero-Martín, A López-Martínez, V Arechavala-Gomeza Neuromuscular Disorders 31, S98, 2021 | | 2021 |
A CRISPR/Cas9 edition protocol for human myoblasts to generate disease models P Soblechero-Martin, E Albiasu-Arteta, A Anton-Martinez, ... HUMAN GENE THERAPY 30 (11), A189-A189, 2019 | | 2019 |
P. 291Overcoming barriers to establish a CRISPR/Cas9 edition protocol for human myoblasts P Soblechero-Martin, E Albiasu-Arteta, J Poyatos-García, ... Neuromuscular Disorders 29, S152, 2019 | | 2019 |